

## **EryDel has CE Marked its New Medical Devices for automatic encapsulation of Drugs into Human Autologous Red Blood Cells**

*ERYDEL SPA Press Release 13 September 2010*

EryDel SpA has reached the certification of its Quality System according to two standards: EN ISO 13485:2003 / AC-2007 and ISO 9001:2008.

EryDel also became qualified medical devices manufacturer by CE marking their new products. The certifications were issued by the **TÜV SÜD Group (EC 0123) notified body** under the European Medical Devices Directive 93/42 and subsequent updates. Purpose of the EC certificate issued by TÜV SÜD Product Service GmbH to EryDel Spa: Design and development, production and distribution of disposable and electro-medical devices for blood processing.

Current medical devices CE marked by EryDel:

- Disposable (single use) Medical device (**ERY-Kit family**) dedicated to blood processing that may subsequently be reinfused to the same donor. More specifically, this is a disposable medical device that allows the encapsulation of Dexamethasone Sodium Phosphate inside red blood cells, that are used as biocompatible carriers and innovative route of administration. The device is non-toxic, non-pyrogenic, supplied sterile in individual package and sterilized with ethylene oxide.



- Electro-medical equipment (**RED CELL LOADER family**). Used in combination with the disposable family ERY-KIT, it is the non-invasive device, fully automatic and highly reproducible, that allows the loading of drugs and other biological agents within red blood cells.



ABOUT ERYDEL ( [www.erydel.com](http://www.erydel.com) )

### **EryDel mission is to develop new innovative therapies**

*EryDel (acronym of ERYthrocyte DELivery) S.p.A. is a company operating in the pharmaceutical field developing products with a proprietary technology.*

*EryDel is a company focused on developing and commercializing of innovative therapies and diagnostic tools based on the use of autologous red blood cells as agent carriers, selective drug targeting system, agent passive reservoirs and circulating bioreactors.*

*The company owns a proprietary technology that allow to encapsulate any kind of active agents within a small quantity of autologous blood with automatic, reliable and a reproducible systems.*

*EryDel is developing its own new therapies and is collaborating with partners for exploiting the possibility to encapsulate their own agents into autologous red blood cells.*